5月4日，“中国医疗器械生产商”天星医疗暗盘涨超400%，总市值超273亿港元，每股定价98.50港元，每手50股；将于5月5日（周二）正式在港交所挂牌交易。
公司是一家立足中国的医疗器械公司，专注于运动医学临床解决方案。据灼识谘询数据，按2024年销售收入计，公司是中国第四大运动医学植入物及器械提供商，市场份额约占中国运动医学植入物及器械市场的6.5%，也是最大的国产运动医学植入物及器械提供商。
依托自主研发的植入物、有源设备、相关耗材及手术工具，公司提供肩袖、韧带、半月板等软组织损伤治疗，也提供运动康复及预防的全方位解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
